Uncover key drivers, emerging technologies, and competitive movements shaping the iron deficiency injectable market from 2026–2035 with trusted insights from The Business Research Company
How much is the Iron Deficiency Injectable Market valued at in 2026, and what valuation is forecast for 2030?
The market for injectable iron deficiency treatments has experienced substantial growth in recent years. It is projected to expand from $15.22 billion in 2025 to $16.74 billion in 2026, at a compound annual growth rate (CAGR) of 10.0%. The historical growth in this market can be attributed to the high prevalence of iron deficiency anemia, the limited efficacy of oral iron therapies, an increasing number of chronic kidney disease cases, the rise of hospital-based infusion treatments, and wider clinical acceptance of injectable iron.
The iron deficiency injectable market size is anticipated to experience substantial growth over the coming years. It is predicted to expand to $25.69 billion by 2030, achieving a compound annual growth rate (CAGR) of 11.3%. This projected growth can be attributed to several factors such as an increasing geriatric population, the rising prevalence of cancer and IBD, the expansion of homecare infusion services, enhanced safety profiles of newer formulations, and improved access to healthcare in emerging markets. Significant trends during the forecast period include a growing preference for injectable iron over oral therapies, its increasing application in chronic kidney disease management, the rise of day-care and short-duration infusion protocols, the expansion of generic injectable iron products, and higher adoption in oncology and chronic disease treatment.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp
What Drivers Are Influencing The Growth Of The Iron Deficiency Injectable Market?
The rising prevalence of polycystic ovary syndrome (PCOS) is expected to propel the growth of the iron deficiency injectables market going forward. Polycystic ovary syndrome (PCOS) is a common hormonal disorder that affects individuals with ovaries, primarily women of reproductive age. PCOS can result in conditions like iron overload, which then leads to excessive blood loss during menstruation, causing anemia in patients. This anemia can be addressed by injectable iron deficiency medications. For instance, in June 2023, according to the World Health Organization, a US-based specialized health agency, polycystic ovary syndrome (PCOS) globally impacts an estimated 8–13% of reproductive-aged women, with 70% of them remaining undiagnosed. Consequently, the widespread occurrence of polycystic ovary syndrome (PCOS) is driving the expansion of the iron deficiency injectables market.
How Is The Iron Deficiency Injectable Market Organized Into Various Segments?
The iron deficiency injectable market covered in this report is segmented –
1) By Type: Iron Dextran, Ferric Carboxymaltose
2) By Branded or Generics: Branded, Generics
3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Ferric Carboxymaltose: Injectafer, Ferinject
What Trends Are Expected To Impact The Competitive Landscape Of The Iron Deficiency Injectable Market?
Leading companies in the iron deficiency injectables market are developing new treatments, such as INJECTAFER, to maintain their market presence. For instance, in June 2023, Daiichi Sankyo Company, a US-based healthcare company, and American Regent Inc., a US-based injectables manufacturer, launched INJECTAFER (ferric carboxymaltose injection) for iron deficiency, which received approval from the Food And Drug Administration, a US-based government agency. This product represents the first and only intravenous iron replacement therapy approved by the FDA for adult patients experiencing chronic and progressive heart failure. INJECTAFER was evaluated in over 40 clinical trials, involving more than 8,800 participants from different countries. This recent approval strengthens INJECTAFER’s proven and effective application in these patients, including adult and pediatric patients with iron-deficient anemia and heart failure.
Who Are The Primary Competitors In The Global Iron Deficiency Injectable Market?
Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Fresenius Medical Care, AbbVie Inc., Bayer AG, AstraZeneca Plc, GSK Plc, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH , Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report
Which Regions Are Poised For Strategic Growth In The Iron Deficiency Injectable Market?
North America was the largest region in the iron deficiency injectable market in 2025. The regions covered in the iron deficiency injectable market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Iron Deficiency Injectable Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=12907&type=smp
Browse Through More Reports Similar to the Global Iron Deficiency Injectable Market 2026, By The Business Research Company
Foundries Market Report 2026
https://www.thebusinessresearchcompany.com/report/foundries-global-market-report
Hemochromatosis Iron Overload Disease Treatment Market Report 2026
Direct Reduced Iron Market Report 2026
https://www.thebusinessresearchcompany.com/report/direct-reduced-iron-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model